-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 8th, there was a change in the pharmaceutical sector, and many stocks hit the daily limit, including Sincerity Pharmaceutical, Yuheng Pharmaceutical, Hainan Haiyao, Xinhua Pharmaceutical, Shuangcheng Pharmaceutical, Dali Pharmaceutical, Baihua Pharmaceutical e.
_Specifically, Sincerity Pharmaceutical set the daily limit at 14:13 on August 8 and closed at the daily limit, the stock price rose 102%, and the closing price was 15 yu.
Analysis believes that the stock's daily limit is due to the hot stock of the pharmaceutical conce.
The company specializes in the research and development, production and sales of chemical raw materials and preparatio.
The main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, gastrodin raw materials, ribavirin and azathioprine raw materials,e.
Yuheng Pharmaceutical closed at the daily limit on the 8th, the stock price rose 84%, and the closing price was 68 yu.
The company is a company engaged in the production and sales of pharmaceutica.
At present, the company's products cover skeletal muscle, cardiovascular and cerebrovascular, vitamin and mineral supplements, anti-infection, anti-tumor and other fiel.
At the same time, the company has gradually made efforts in the field of CMO in recent years, and has a certain position in this fie.
Hainan Haiyao closed at the daily limit at 66 yuan, with a total market value of 05 billi.
The company's main business is the research and development, production and sales of drugs and medical devic.
In the news, the company announced that it intends to pre-list and transfer its 43% stake in Shanghai Lishengte on the Beijing Equity Exchange, with a target of a net loss of 85 billion yuan from January to March this ye.
If it can be successfully completed, Shanghai Lishengte will no longer be included in the scope of the company's consolidated statements, which will have a certain impact on the company's total assets, operating income, and net prof.
Xinhua Pharmaceuticals also closed at the daily limit, with the stock price up 100% and the closing price at 245 yu.
The company is mainly engaged in the development, manufacture and sale of chemical raw materials, preparations and chemical products; the company's main products include antipyretic and analgesic raw materials, tablets, injections, capsules, and pharmaceutical intermediat.
The reason for its daily limit is mainly related to Azvudine tablets, and the company has established a cooperative relationship with Real Biolo.
Shuangcheng Pharmaceutical closed at the daily limit, the stock price rose 96%, and the closing price was 30 yu.
According to the data, the company's main business is the research and development, production and sales of chemically synthesized peptide dru.
The main products include Jitai (brand name) Thymosin for Injection, Bivalirudin for Injection, L-carnitine for Injection, Clindamycin Hydrochloride for Injection, Famotidine for Injection, Somatostatin for Injection, Ligustrazine Phospha.
Dali Pharmaceutical closed at the daily limit on August 8, the stock price rose 103%, and the closing price was 100 yu.
The company's main business is the production and sales of Chinese and Western medicine injectio.
The main products are "Zhongjing Brand" Xingnaojing Injection and Shenmai Injecti.
Analysis believes that the stock's daily limit is related to these two dru.
Baihua Pharmaceutical closed at the daily limit on the 8th, the stock price rose 100%, and the closing price was 71 yu.
The company's main business is drug discovery, research, and technical services, providing full-process services and integrated solutions from drug discovery to CMC, clinical CRO, drug registration, CMO/API supply and other new drug development process.
Judging from the reasons for the daily limit of the above-mentioned daily limit stocks, it is mainly related to the strong intraday rise of the new crown drug concept on the 8.
Some institutions said that the approval and listing of domestic oral therapeutic drugs will help hospital diagnosis and treatment activities and even social life to return to norm.
The performance of listed companies in the pharmaceutical industry is expected to usher in marginal improvement in the third quarter, which will greatly benefit the pharmaceutical sector; direct benefits Regarding the approved upstream and downstream enterprises Xinhua Pharma, China Resources Shuanghe, Aoxiang Pharmaceutical, Fosun Pharma, and small-molecule oral drugs that may be approved in the future, relevant companies including Junshi Biotechnology and Simcere Pharmaceuticals also suggested Active attenti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
_Specifically, Sincerity Pharmaceutical set the daily limit at 14:13 on August 8 and closed at the daily limit, the stock price rose 102%, and the closing price was 15 yu.
Analysis believes that the stock's daily limit is due to the hot stock of the pharmaceutical conce.
The company specializes in the research and development, production and sales of chemical raw materials and preparatio.
The main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, gastrodin raw materials, ribavirin and azathioprine raw materials,e.
Yuheng Pharmaceutical closed at the daily limit on the 8th, the stock price rose 84%, and the closing price was 68 yu.
The company is a company engaged in the production and sales of pharmaceutica.
At present, the company's products cover skeletal muscle, cardiovascular and cerebrovascular, vitamin and mineral supplements, anti-infection, anti-tumor and other fiel.
At the same time, the company has gradually made efforts in the field of CMO in recent years, and has a certain position in this fie.
Hainan Haiyao closed at the daily limit at 66 yuan, with a total market value of 05 billi.
The company's main business is the research and development, production and sales of drugs and medical devic.
In the news, the company announced that it intends to pre-list and transfer its 43% stake in Shanghai Lishengte on the Beijing Equity Exchange, with a target of a net loss of 85 billion yuan from January to March this ye.
If it can be successfully completed, Shanghai Lishengte will no longer be included in the scope of the company's consolidated statements, which will have a certain impact on the company's total assets, operating income, and net prof.
Xinhua Pharmaceuticals also closed at the daily limit, with the stock price up 100% and the closing price at 245 yu.
The company is mainly engaged in the development, manufacture and sale of chemical raw materials, preparations and chemical products; the company's main products include antipyretic and analgesic raw materials, tablets, injections, capsules, and pharmaceutical intermediat.
The reason for its daily limit is mainly related to Azvudine tablets, and the company has established a cooperative relationship with Real Biolo.
Shuangcheng Pharmaceutical closed at the daily limit, the stock price rose 96%, and the closing price was 30 yu.
According to the data, the company's main business is the research and development, production and sales of chemically synthesized peptide dru.
The main products include Jitai (brand name) Thymosin for Injection, Bivalirudin for Injection, L-carnitine for Injection, Clindamycin Hydrochloride for Injection, Famotidine for Injection, Somatostatin for Injection, Ligustrazine Phospha.
Dali Pharmaceutical closed at the daily limit on August 8, the stock price rose 103%, and the closing price was 100 yu.
The company's main business is the production and sales of Chinese and Western medicine injectio.
The main products are "Zhongjing Brand" Xingnaojing Injection and Shenmai Injecti.
Analysis believes that the stock's daily limit is related to these two dru.
Baihua Pharmaceutical closed at the daily limit on the 8th, the stock price rose 100%, and the closing price was 71 yu.
The company's main business is drug discovery, research, and technical services, providing full-process services and integrated solutions from drug discovery to CMC, clinical CRO, drug registration, CMO/API supply and other new drug development process.
Judging from the reasons for the daily limit of the above-mentioned daily limit stocks, it is mainly related to the strong intraday rise of the new crown drug concept on the 8.
Some institutions said that the approval and listing of domestic oral therapeutic drugs will help hospital diagnosis and treatment activities and even social life to return to norm.
The performance of listed companies in the pharmaceutical industry is expected to usher in marginal improvement in the third quarter, which will greatly benefit the pharmaceutical sector; direct benefits Regarding the approved upstream and downstream enterprises Xinhua Pharma, China Resources Shuanghe, Aoxiang Pharmaceutical, Fosun Pharma, and small-molecule oral drugs that may be approved in the future, relevant companies including Junshi Biotechnology and Simcere Pharmaceuticals also suggested Active attenti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
